Table 3.
Summary of the coverage of various dosage regimens for the pathogen isolates with MICs of ≥16 mg/L at the condition of achieving ≥90% PTA and/or the targeted pathogen population with pooled MIC distributions between 16 and 512 mg/L at the condition of achieving ≥90% CFR in different types of infection.
| Dosing models | Dosage regimen | Covered pathogen isolates and/or populations in various types of the infection at different PD targets | ||
|---|---|---|---|---|
| 50% fT > MIC | 50% fT > 2 × MIC | 50% fT > 5 × MIC | ||
|
Mainly for bacterial peritonitis or intraabdominal infections, bloodstream infections, skin and soft tissue infections, or urinary tract infections |
Mainly for bacterial hepatitis, metritis, oophoritis, proctitis, or prostatitis, etc. |
Mainly for LRTIs, such as pneumonia, bronchitis, or pleural infections |
||
| 0.5 g q 8 h | 0.5 g (4 h) | NA | NA | NA |
| 0.5 g (5 h) | NA | NA | NA | |
| 0.5 g (6 h) | NA | NA | NA | |
| 0.25 g (5-min IVB) + 0.25 g (4 h) | NA | NA | NA | |
| 0.25 g (5-min IVB) + 0.25 g (5 h) | P16+(AS, SM) | NA | NA | |
| 0.25 g (5-min IVB) + 0.25 g (6 h) | P16+(AS, SE, SM) | NA | NA | |
| 1 g q 8 h | 1 g (4 h) | NA | NA | NA |
| 1 g (5 h) | NA | NA | NA | |
| 1 g (6 h) | NA | NA | NA | |
| 0.5 g (5-min IVB) + 0.5 g (4 h) | P16+(AS, SM) | NA | NA | |
| 0.5 g (5-min IVB) + 0.5 g (5 h) | P32+(AS, PA, SE, SHA, SM) | P16+(SE, SM) | NA | |
| 0.5 g (5-min IVB) + 0.5 g (6 h) | P32+(AB, AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | NA | |
| 2 g q 8 h | 2 g (4 h) | NA | NA | NA |
| 2 g (5 h) | NA | NA | NA | |
| 2 g (6 h) | NA | NA | NA | |
| 0.5 g (5-min IVB) + 1.5 g (4 h) | P32+(AS, SE, SM) | P16+(AS, SM) | NA | |
| 0.5 g (5-min IVB) + 1.5 g (5 h) | P32+(AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | NA | |
| 0.5 g (5-min IVB) + 1.5 g (6 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, PA, SE, SHA, SM) | P16+(AS, SM) | |
| 1 g (5-min IVB) + 1 g (4 h) | P32+(AS, PA, SE, SHA, SM) | P16+(AS, SM) | NA | |
| 1 g (5-min IVB) + 1 g (5 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, PA, SE, SHA, SM) | NA | |
| 1 g (5-min IVB) + 1 g (6 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | |
| 1.5 g (5-min IVB) + 0.5 g (4 h) | P32+(AS, PA, SE, SHA, SM) | P16+(AS, SE, SM) | NA | |
| 1.5 g (5-min IVB) + 0.5 g (5 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, PA, SE, SHA, SM) | P32+(AS, PA, SE, SHA, SM) | |
| 1.5 g (5-min IVB) + 0.5 g (6 h) | P128+(AB, AS, EFM, PA, SE, SHA, SM) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | |
| 0.75 g q 6 h | 0.75 g (4 h) | NA | NA | NA |
| 0.75 g (5 h) | NA | NA | NA | |
| 0.75 g (6 h) | NA | NA | NA | |
| 0.5 g (5-min IVB) + 0.25 g (4 h) | P32+(AS, SE, SM) | P16+(AS, SM) | NA | |
| 0.5 g (5-min IVB) + 0.25 g (5 h) | P32+(AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | NA | |
| 0.5 g (5-min IVB) + 0.25 g (6 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P64+(AS, PA, SE, SHA, SM) | NA | |
| 1.5 g q 6 h | 1.5 g (4 h) | NA | NA | NA |
| 1.5 g (5 h) | NA | NA | NA | |
| 1.5 g (6 h) | NA | NA | NA | |
| 0.5 g (5-min IVB) + 1 g (4 h) | P32+(AS, PA, SE, SHA, SM) | P16+(AS, SE, SM) | NA | |
| 0.5 g (5-min IVB) + 1 g (5 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, PA, SE, SHA, SM) | NA | |
| 0.5 g (5-min IVB) + 1 g (6 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AB, AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | |
| 1 g (5-min IVB) + 0.5 g (4 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, SE, SM) | NA | |
| 1 g (5-min IVB) + 0.5 g (5 h) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P32+(AS, EFM, PA, SE, SHA, SM) | P16+(AS, SE, SM) | |
| 1 g (5-min IVB) + 0.5 g (6 h) | P128+(AB, AS, EFM, PA, SE, SHA, SM) | P64+(AB, AS, EFM, PA, SE, SHA, SM) | P16+(AS, PA, SE, SM) | |
AB, Acinetobacter baumannii; AS, Acinetobacter spp.; EFS, Enterococcus faecalis; EFM, Enterococcus faecium; PA, Pseudomonas aeruginosa; SE, Staphylococcus epidermidis; SHA, Staphylococcus haemolyticus; SM, Stenotrophomonas maltophilia.
NA, not applicable.
P16, P32, P64, P128 signify the pathogen isolates with MICs of 16, 32, 64, and 128 mg/L, respectively.
Regimens with Px (x = 16, 32, 64 or 128) + (y) (y = AB, AS, EFM, PA, SE, SHA, SM, or a combination) signify that they are competent for the treatment of infections caused by the pathogen isolates actually found at that MIC if the exact MIC values are available and/or for the treatment of infections caused by the targeted pathogen population identified with only bacterial species if the exact MIC values are unavailable.